Tislelizumab Combo Shows Promise in HER2-Negative Gastric/GEJ Cancer
January 24th 2025Tislelizumab combined with irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin proved effective with manageable safety as frontline therapy for advanced HER2-negative, mismatch repair–proficient gastric and GEJ adenocarcinoma in the SYLT-023 trial.
Read More
Nivolumab Plus Chemo Improves OS in Chinese Patients With Advanced Gastric/GEJ Cancer
January 23rd 2025The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Read More
5-Year Update Sustains Nivolumab/Chemo Efficacy in Frontline Gastric/GEJ/Esophageal Cancer
January 23rd 20255-year follow-up results from the phase 3 CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.
Read More
Everolimus Plus Lanreotide Shows PFS Benefit in Unresectable/Recurrent GEP-NETs
January 21st 2025The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
Read More
Promising Activity in MSS CRC with Innovative Drug Combined with Bevacizumab and Chemotherapy
January 20th 2024In the DeFianCe trial, the combination of DKN-01 with bevacizumab and chemotherapy is being investigated to assess the potential clinical benefits for patients diagnosed with microsatellite stable colorectal adenocarcinoma.
Read More
First-Line Nivolumab Plus Ipilimumab Demonstrates Superior PFS in mCRC
January 20th 2024Results from the phase 3 CheckMate-8HW trial support first-line treatment with nivolumab plus ipilimumab as a standard-of-care option for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer.
Read More
Regorafenib Discontinuation More Likely With Poor Liver Function in Liver Cancer
January 19th 2024Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.
Read More